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Abstract
The field of cellular therapy of cancer is moving quickly and the issues involved with its advancement are complex
and wide ranging. The growing clinical applications and success of adoptive cellular therapy of cancer has been
due to the rapid evolution of immunology, cancer biology, gene therapy and stem cell biology and the translation
of advances in these fields from the research laboratory to the clinic. The continued development of this field is
dependent on the exchange of ideas across these diverse disciplines, the testing of new ideas in the research
laboratory and in animal models, the development of new cellular therapies and GMP methods to produce these
therapies, and the testing of new adoptive cell therapies in clinical trials. The Summit on Cell Therapy for Cancer to
held on November 1 and 2, 2011 at the National Institutes of Health (NIH) campus will include a mix of
perspectives, concepts and ideas related to adoptive cellular therapy that are not normally presented together at
any single meeting. This novel assembly will generate new ideas and new collaborations and possibly increase the
rate of advancement of this field.
Review
On November 1 and 2, 2011 at the National Institutes
of Health (NIH) campus in Bethesda, Maryland a multi-
disciplinary summit of laboratory and clinical investiga-
tors and individuals involved in the clinical use,
manufacture, evaluation and regulation of cellular thera-
pies for the treatment of cancer will meet to discuss the
most recent advances and promising cellular therapies
of cancer (http://www.sitcancer.org/meetings/am11/
summit11). The meeting is sponsored by the Society for
Immunotherapy of Cancer (SITC). The purpose of this
Summit is to bring clinical and laboratory investigators
and those involved with producing, assessing and regu-
lating cellular therapies, together to present and discuss
important scientific and technical advances that cur-
rently or will soon impact the field.
The Summit is important because this field is moving
quickly and the issues involved with its advancement are
complex and wide ranging. Regular, more focused
immune therapy of cancer meetings remain important
and, in fact, are critical to the advancement of adoptive
cellular therapy of cancer, but this and most other areas
of clinical therapy will benefit from the cross-fertiliza-
tion that results from the interactions with other related
clinical fields, regulatory agencies and industry.
While immunology, cell biology and cancer biology
have been the cornerstones of adoptive cellular therapy,
gene transfer, cell reprogramming and stem cell biology
are emerging as important contributors to this field. All
of these areas will be discussed at the Summit on Cell
Therapy for Cancer. The meeting will include lectures
on adoptive cellular therapy using tumor infiltrating
lymphocytes (TIL), cytotoxic T cells and natural killer
(NK) cells, reprogramming immune and stem cells, new
methods for cell expansion, regulatory considerations
and bringing new technologies from the research labora-
tory to the clinic.
The clinical promise of cellular therapies is growing
rapidly. The treatment of metastatic melanoma with
TIL, which was pioneered byt h eS u r g e r yB r a n c h ,N C I ,
NIH, is becoming more effective and its use is becoming
more widespread. Since TIL were first used to success-
fully treat melanoma is 1988 [1], several improvements
have been made. Preconditioning patients with
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portion of patients with objective clinical responses to
50% [2]. Further intensification of the lymphocyte
depleting preconditioning using cyclophosphamide, flu-
darabine and total body irradiation (TBI) along with
marrow rescue by the administration of autologous
CD34+ isolated from G-CSF mobilized peripheral blood
stem cell products improved objective clinical response
rates to 72% [3,4]. Several institutions are now using
TIL to treat melanoma [4-7]. Other groups have used
expanded antigen specific CD8+ T cells for adoptive cel-
lular therapy of melanoma [8-11]. Some investigators are
using autologous dendritic cells or artificial antigen pre-
senting cells pulsed with tumor antigens to expand cyto-
toxic T cells for melanoma therapy [8,9].
Immune therapy of cancer has spread well beyond the
treatment of melanoma. The field of hematopoietic stem
cell transplantation (HSCT) is moving from a cell repla-
cement therapy to an adoptive cellular therapy. In fact,
in many respects the fields of immune therapy of cancer
and HSCT are merging. The non-myleoablative che-
motherapy and TBI regimen and autologous CD34+ cell
rescue used as part of adoptive cellular therapy proto-
cols used to treat metastatic melanoma are similar to
those used for HSCT. For many years lymphocytes col-
lected from HSCT donors have been infused following
HSCT as an adoptive cellular therapy to treat leukemia
relapse following transplantation; particularly chronic
myelogenous leukemia [12]. Lymphocytes from the
HSCT donor are also being used to treat Epstein-Barr
virus (EBV) associated B cell lymphoproliferative disease
in HSCT recipients. These post-transplant lymphoproli-
ferative diseases (PTLDs) occur most often in recipients
of T cell depleted grafts. PTLD can be treated with the
infusion of unmanipulated donor lymphocytes, but this
is associated with a high risk of graft-versus-host disease
(GVHD). In order to avoid GVHD, PTLDs are being
treated with donor derived EBV-specific T cells [13,14].
These EBV-specific T cells are generated by culturing
donor peripheral blood mononuclear cells (PBMCs)
with EBV-transformed lymphoblastoid B cell lines (LCL)
which effectively express EBV antigens and function as
antigen presenting cells. Treatment of PTDL with EBV-
specific cytotoxic T lymphocytes (CTLs) is effective in
more than 80% of patients, and when used prophylaxti-
cally in high risk patients is effective at preventing
PTDL [15].
A number of groups are investigating the use of T
cells specific to the leukemia antigens such as Wilms
tumor 1 (WT1) [16,17] and proteinase 3 (PR3) [18] to
prevent or treat leukemia relapse following HSCT. In
addition, recently, vaccination has been able to induce
robust T cell responses against cancer-associated anti-
gens such as viral oncogenic proteins [19]. This offers
the prospect to combine proper vaccine strategies with
adoptive transfer of specific T cells to achieve optimal T
cell expansion and therapeutic benefit [20].
Adoptive cellular therapy protocols have also begun to
use NK cells. Clinical investigators interested in treating
both cancer and hematologic malignancies and leukemia
have been using both allogeneic and autologous natural
killer (NK) cells as adoptive cellular therapy. To treat
disease relapse in HSCT recipients with hematologic
malignancies NK cells from the HSCT donors are being
administering post-transplant. Peripheral blood mono-
nuclear cells (PBMCs) collected from the HLA-matched
donors are enriched for NK cells by the depletion of
CD3+ T cells using anti-CD3 immunomagentic beads or
by CD3+ T cell depletion followed by CD56+ cell selec-
tion [21]. The allogeneic NK cells are administered to
the recipient at the time of disease relapse. The NK cell
recipient is immunosuppressed and treated with IL-2 to
allow for in vivo NK cell expansion. This NK cell ther-
apy has resulted in complete hematological remission in
5 of 19 patients treated with acute myelogenous leuke-
mia [22]. Similar NK cell preparations and treatment
protocols have been used to treat patients with recur-
rent breast cancer and ovarian cancer [23] and refrac-
tory lymphoma [24]. The patients were given a
lymphodepleting preparative regimen and were then
treated with NK cells from HLA haplotype identical
donors followed by 6 doses of IL-2 therapy. Among the
6 patients with refractory lymphoma, 4 have had objec-
tive clinical responses [24].
Other investigators are using ex vivo expanded autolo-
gous NK cells as primary therapy for cancer [25]. Auto-
logous NK cells were isolated using a two step process
from PBMC products collected from the patient by
apheresis. PBMCs in the apheresis product are depleted
of T cell using anti-CD3 immunomagentic beads and
then NK cells are selected using anti-CD56 immunoma-
gentic beads. The isolated NK cells are then expanded
by incubation with lymphoblastoid cell lines (LCLs) as
feeder cells and IL-2. The autologous expanded NK cells
are being used to treat patients with advanced malignan-
cies [26].
Gene therapy is becoming an important part of cellu-
lar therapy for cancer and hematologic malignancies,
particularly, dendritic cell (DC) therapy. DCs have been
used in many clinical trials of immunotherapy for can-
cer. For these studies DCs are usually generated by
incubating peripheral blood monocytes with the differ-
entiating agents IL-4 and GM-CSF to produce immature
DCs (iDCs) which are used for some clinical trials, but
for most trials iDCs are incubated with maturation
agents to produce mature DCs (mDCs) [27]. Typically,
DCs are loaded with immune dominant peptides or pro-
teins prior to their administration [8,9], however, many
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to epitope-load HLA antigens [17]. For many years
adoptive cellular therapy using genetically engineered
cells has been used to treat Hodgkin’s lymphoma. The
same EBV-specific CTLs that have used to treat PTLD
have also been used to treat EBV-positive Hodgkin’s
Disease (EBV-HD) [14]. While some patients responded
to this therapy, the frequency of T cell clones recogniz-
ing the EBV antigen expressed in Hodgkin’s disease,
LMP2, is low. As a result LMP2 specific CTLs were gen-
erated by first culturing T cells with DCs transduced
with recombinant adenovirus encoding LMP2A followed
by expansion by culture with LCL transduced with the
same vector [14]. The treatment of 6 patients with high
risk EBV-associated lymphomas in relapse with these
LMP2 specific CTLs resulted in clinical responses in 5
patients [28].
Another very promising use of genetically engineered
cells for the treatment of cancer involves arming autolo-
gous T cells with T cell receptors (TCR) that have a
high affinity to cancer antigens, expanding these geneti-
cally modified T cells in vitro and infusing them into
patients [29]. T cells transduced with a high affinity
TCRs for the melanoma antigens MART-1 and gp100
are being used to treat patients with metastatic mela-
noma [30,31]. Clinical responses were seen in 19% and
30% of patients [30,31]. In addition, high affinity TCRs
specific for NY-ESO-1, a cancer antigen expressed by
approximately 80% of patients with synovial cell sar-
coma and 25% with melanoma, are being transduced
into autologous T cells, the T cells are being expanded
ex vivo and used to treat patients with metastatic syno-
vial cell sarcoma and metastatic melanoma [32]. This
therapy has resulted in objective clinical responses in 4
of 6 patients with synovial cell sarcoma and five of 11
patients with melanoma [32].
Chimeric antigen T cell receptors (CAR) are also
being used in adoptive cell therapy of cancer. One CAR
that has been tested clinically is made up of the antigen
recognition portion of CD19, the zeta chain of the T
cell receptor and a portion of the co-stimulatory mole-
cule CD28. Autologous T cells transduced with anti-
CD19 CAR are cytolytic to B cell lymphoma cells that
express CD19 [33]. While clinical trials of these geneti-
cally engineered T cells are just beginning, preliminary
results have been encouraging [34].
In order to improve the effectiveness of adoptive cel-
lular therapies with engineered T cells clinical investiga-
tors have turned to stem cell biology. While any
population of CD8+ T cells can be genetically engi-
neered; naïve, central memory or effector memory cells,
engineered T cells produced from these three different
types of T cells may not be equally effective in treating
cancer. Restifo and colleagues have recently shown that
naïve T cells are more capable then central or effector
memory T cells of expressing TCR transgenes and in
vitro expansion. Furthermore, expanded naïve cells
express lower levels of markers of effector differentiation
which has been associated with greater adoptive cellular
therapy effectiveness and higher levels of CD27 and
longer telomeres, which suggests that these cells have a
greater in vivo proliferation potential [35]. The number
of naïve T cells in the circulation varies among healthy
subjects [35] and the levels of circulating native T cells
are likely to be more variable among cancer patients
due to prior cancer chemotherapy or the cancer itself.
Patients who have had extensive chemotherapy may
have very low levels of circulating T cells. As a result,
investigators are working on cell reprogramming strate-
gies to produce naïve and stem T cells for adoptive cel-
lular therapy.
Patients are not served until new therapies are
brought to the clinic. Fortunately, the clinical success of
adoptive cellular therapies currently in clinical trials is
driving the development of new cell production technol-
ogies that will make adoptive cellular therapy more fea-
sible. Investigators at Baylor have found that gas-
permeable flasks (e.g., G-Rex flasks, Wilson Wolf Manu-
facturing, New Brighton, MN) can be used to expand
cytotoxic T cells to a much higher concentration than
bags or traditional flasks [36]. Cell culture in G-Rex gas-
permeable flasks requires approximately one-fifth the
quantity of media, AB Serum, IL-2 and anti-CD3, and
less equipment than culturing in bags or flasks. This
reduction in culture volume and media is extremely
important to producing the 10 to 40 × 10
9 cell used for
adoptive cytotoxic T cell and NK cell therapy. Several
groups are currently working to develop and validate
methods to expand, TIL, T cells, engineered T cells and
NK cell in G-Rex gas-permeable flasks. If the promising
preliminary results of T and NK cell growth and expan-
sion in G-Rex flasks continues, these methods will likely
lead to the more widespread use many adoptive cellular
therapies. Cell therapy laboratories are also working
with the manufacturer of the G-Rex flasks, Wilson Wolf
Manufacturing, to produce a larger gas-permeable flasks
specifically designed for good manufacturing practice
(GMP) cell growth that will further simply TIL, T cell
and NK cell production.
Adoptive cell therapy requires cell growth and culture
in multiple types of flasks and bags, with a variety of
growth factors, cytokines and antibodies. Cell selection
or depletion using monoclonal antibodies or elutriation
is often used. Cells are sometimes transduced with ret-
roviral or lentiviral vectors. Bringing these complex
therapies to the clinic requires investigators to address a
number of issues related to the safety and effectiveness
of the final product. The United States Food and Drug
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safe and effective adoptive cellular therapies to the clinic
and addressing the complex regulator issues related to
cellular therapies. Representatives from the FDA should
be included in forums that address important issues in
the field of adoptive cellular therapy of cancer.
The growing clinical applications and success of adop-
tive cellular therapy of cancer has been due to the rapid
evolution of immunology, gene therapy and stem cell
biology and the translation of advances in these fields
from the research laboratory to the clinic. The contin-
ued development of this field is dependent on the
exchange of ideas across these diverse disciplines, the
testing of new ideas in the research laboratory and in
animal models, the development of new cellular thera-
pies and GMP methods to produce these therapies, and
the testing of new adoptive cell therapies in clinical
trials. The Summit on Cell Therapy for Cancer will
include a mix of perspectives, concepts and ideas related
to adoptive cellular therapy that are not normally pre-
sented together at any single meeting. We hope that
this novel assembly will generate new ideas and new
collaborations and possibly increase the rate of advance-
ment of this field.
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